Drugs / Gastrin-17
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03746769 | Jul 2019 → Aug 2028 expected | type 1 diabetes mellitus | City of Hope Medical Center | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01909245 Background | Oct 2013 → Sep 2026 expected | type 1 diabetes mellitus | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gastrin-17 | “Gastrin-17 (or GAST-17) - a gut hormone injected under the skin twice daily for 30 days soon after islet transplant and again 6 months later.” NCT03746769 ↗2“Gastrin-17 (or GAST-17) - a gut hormone injected under the skin for 30 days (optional treatment for islet dysfunction).” NCT01909245 ↗ |
| Known as | GAST-17 | “Gastrin-17 (or GAST-17) - a gut hormone injected under the skin twice daily for 30 days soon after islet transplant and again 6 months later.” NCT03746769 ↗ |
| Route | Subcutaneous | “injected under the skin” NCT01909245 ↗ |